Literature DB >> 10515086

Estrogen receptors in the human male prostatic urethra and prostate in prostatic cancer and benign prostatic hyperplasia.

A Bødker1, J Bruun, E Balslev, H G Iversen, H H Meyhoff, K E Andersson.   

Abstract

Estrogen receptors (ERs) in the prostate and prostatic urethra were examined in 33 men with benign prostatic hyperplasia (BPH) and in 11 with prostate cancer (PC). The Abbot monoclonal ER-ICA assay was used for immunohistochemical investigation. In the BPH group, ERs were revealed in the prostatic stroma in eight cases and in the glandular epithelium in one. In four cases ERs were seen in the prostatic stroma and in the glandular epithelium. In the prostatic urethra, ERs were found in 19 cases located in the urothelium, lamina propria and/or periurethral glands. In the PC group, ERs were demonstrated in the prostatic stroma and/or prostatic urethra in 6 out of 11 cases. In both BPH and PC patients, immunoreactivity was weak and confined to few cells, indicating low ER content in the prostate as well as in the prostatic urethra. Dextran-coated charcoal (DCC) analysis was used for detection and quanticization of cytosolic and nuclear ERs. In the BPH group, ERs were detected once in the prostate and prostatic urethra in the nuclear and cytosol, and additionally in the prostatic urethra in the cytosol fraction in three cases. In all cases, ER content was low, ranging from 10-15 fmol/mg protein. In the PC group, ERs were detected in the prostatic urethra and/or prostate in the cytosol fraction from two patients. The contents were low, ranging from 10-13 fmol/mg protein. We conclude that in human BPH and PC, ERs can be present in the prostate and prostatic urethra. In the prostate, ERs are mainly located in the stroma, but in BPH specimens they can also be found in the glandular epithelium. Biochemically, the use of the DCC analysis is of limited value, since ER content in the human prostate and prostatic urethra is at the limit of detection with this method.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10515086     DOI: 10.1080/003655999750015844

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  5 in total

1.  Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia.

Authors:  Rui Yang; Yu-Xia Ma; Lin-Feng Chen; Ying Zhou; Zhan-Po Yang; Yan Zhu; Xiao-Ling Du; Jian-Dang Shi; Hong-Shun Ma; Ju Zhang
Journal:  Asian J Androl       Date:  2010-05-17       Impact factor: 3.285

Review 2.  Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk.

Authors:  Mitchell S Steiner; Sharan Raghow
Journal:  World J Urol       Date:  2003-02-14       Impact factor: 4.226

3.  Estrogen receptor-α is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia.

Authors:  Tristan M Nicholson; Michael A Moses; Kristen S Uchtmann; Kimberly P Keil; Dale E Bjorling; Chad M Vezina; Ronald W Wood; William A Ricke
Journal:  J Urol       Date:  2014-08-25       Impact factor: 7.450

Review 4.  Importance of Estrogenic Signaling and Its Mediated Receptors in Prostate Cancer.

Authors:  Kin-Mang Lau; Ka-Fai To
Journal:  Int J Mol Sci       Date:  2016-08-31       Impact factor: 5.923

5.  Relationship of oestrogen receptor alpha gene polymorphisms with risk for benign prostatic hyperplasia and prostate cancer in Chinese men.

Authors:  Zihua Han; Lingzhi Zhang; Rujian Zhu; Lifei Luo; Min Zhu; Lilong Fan; Guanfu Wang
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.